| Keywords: |
genetics; clinical trial; review; methodology; endometrial neoplasms; neoplasm; mouse; animal; animals; mice; estrogen; estrogens; mass screening; drug effect; pathology; breast neoplasms; risk; nude mouse; mice, nude; chemically induced disorder; breast tumor; hyperplasia; carcinoma; tamoxifen; receptors, estrogen; phenols; neoplasms, second primary; neoplasm transplantation; antineoplastic agents, hormonal; second cancer; genes, ras; leiomyosarcoma; estrogen receptor; menopause; endometrium tumor; oncogene ras; antineoplastic hormone agonists and antagonists; clinical trials; polyp; polyps; antiestrogen; endometrium; neoplasms, hormone-dependent; cancer transplantation; phenol derivative; alkene; alkenes; estrogen antagonists; humans; human; female; 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene; 4 (1,2 diphenyl 1 buten 1 yl)phenol
|
